ConductScience.org, home

Paper3988341

Synergistic effect of glucantime and a liposome-encapsulated muramyl dipeptide analog in therapy of experimental visceral leishmaniasis.

Adinolfi LE and 3 others. Infect Immun, 1985. Cited by 34 papers, by iCite.

Cite this record

ConductScience Library. Synergistic effect of glucantime and a liposome-encapsulated muramyl dipeptide analog in therapy of experimental visceral leishmaniasis. Papers, record 3988341. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/3988341

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Synergistic effect of glucantime and a liposome-encapsulated muramyl dipeptide analog in therapy of experimental visceral leishmaniasis.
PubMed
Journal
Infect Immun
PubMed
Year
1985
PubMed
Publication types
Journal Article, Research Support, Non-U.S. Gov't
PubMed
Citations, by iCite
34
iCite
Relative citation ratio, by iCite
1.39
iCite
Revised in PubMed
2021-05-26
PubMed

Authors4

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Adinolfi LEL E
2Bonventre PFP F
3Vander Pas MM
4Eppstein DAD A

Source PubMed

Download CSV of authors

Topics16

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Acetylmuramyl-Alanyl-IsoglutamineMajor topic
Adjuvants, ImmunologicMajor topic
AntimonyMajor topic
Antiprotozoal AgentsMajor topic
Leishmaniasis, VisceralMajor topic
MeglumineMajor topic
Organometallic CompoundsMajor topic
Animals
Combined Modality Therapy
Cricetinae
Female
Meglumine Antimoniate
Mesocricetus
Mice
Mice, Inbred BALB C
Mice, Inbred C57BL

Source PubMed

Download CSV of topics

References47

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
16356272The immunobiology of leishmaniasis.Rev Infect Dis1983https://conductscience.org/library/papers/6356272PubMed
26638931Non-specific and specific stimulation of resistance against Leishmania donovani in C57BL/6 mice.Ann Clin Lab Sci1983https://conductscience.org/library/papers/6638931PubMed
36365745Stimulation of macrophage protease secretion via liposomal delivery of muramyl dipeptide derivatives to intracellular sites.Immunology1984https://conductscience.org/library/papers/6365745PubMed
46231248Immunoregulation of genetically controlled acquired responses to Leishmania donovani infection in mice: demonstration and characterization of suppressor T cells in noncure mice.Infect Immun1984https://conductscience.org/library/papers/6231248PubMed
56543694Prophylaxis and treatment of experimental lung metastases in mice after treatment with liposome-encapsulated 6-O-stearoyl-N-acetylmuramyl-L-alpha-aminobutyryl-D-isoglutamine.Clin Exp Metastasis1984https://conductscience.org/library/papers/6543694PubMed
74187176Problems in leishmaniasis related to immunology.Curr Top Microbiol Immunol1969https://conductscience.org/library/papers/4187176PubMed
84606813Minimal structural requirements for adjuvant activity of bacterial peptidoglycan derivatives.Biochem Biophys Res Commun1974https://conductscience.org/library/papers/4606813PubMed
94214869Cellular immunity to Leishmania donovani. I. The effect of T cell depletion on resistance to L. donovani in mice.J Immunol1974https://conductscience.org/library/papers/4214869PubMed
101065901Modulation of the immune response by a synthetic adjuvant and analogs.Proc Natl Acad Sci U S A1976https://conductscience.org/library/papers/1065901PubMed
11321136Target cells for the activity of a synthetic adjuvant: muramyl dipeptide.Cell Immunol1977https://conductscience.org/library/papers/321136PubMed
12325566Enhancement of nonspecific immunity to Klebsiella pneumoniae infection by a synthetic immunoadjuvant (N-acetylmuramyl-L-alanyl-D-isoglutamine) and several analogs.Proc Natl Acad Sci U S A1977https://conductscience.org/library/papers/325566PubMed
13873609Effect of treatment with BCG on the course of visceral leishmaniasis in BALB/c mice.Infect Immun1977https://conductscience.org/library/papers/873609PubMed
14563773In vitro spleen cell responsiveness to various analogs of MDP (N-acetylmuramyl-L-alanyl-D-isoglutamine), a synthetic immunoadjuvant, in MDP high-responder mice.Cell Immunol1978https://conductscience.org/library/papers/563773PubMed
15313841The adjuvant activity of synthetic N-acetylmuramyl-dipeptide: evidence of initial target cells for the adjuvant activity.Cell Immunol1979https://conductscience.org/library/papers/313841PubMed
16113344Enhancement of host resistance against Trypanosoma cruzi infection by the immunoregulatory agent muramyl dipeptide.Infect Immun1979https://conductscience.org/library/papers/113344PubMed
177384789Therapy of spontaneous metastases by intravenous injection of liposomes containing lymphokines.Science1980https://conductscience.org/library/papers/7384789PubMed
187392013Visceral leishmaniasis in mice: protective effect of glucan.J Reticuloendothel Soc1980https://conductscience.org/library/papers/7392013PubMed
196967358Components of mycobacteria and muramyl dipeptide with adjuvant activity induce lymphocyte activating factor.Cell Immunol1980https://conductscience.org/library/papers/6967358PubMed
20551094Fate of the synthetic immunoadjuvant, muramyl dipeptide (14C-labelled) in the mouse.Int J Immunopharmacol1979https://conductscience.org/library/papers/551094PubMed
217441647Muramyl dipeptide stimulation of particle clearance in several animal species.J Reticuloendothel Soc1980https://conductscience.org/library/papers/7441647PubMed

See all 47 referencesDownload CSV of references

Cited by11

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 34 citations.

PMIDTitleJournalYearIn PapersSource
35779182The Possible Role of Selected Vitamins and Minerals in the Therapeutic Outcomes of Leishmaniasis.Biol Trace Elem Res2023https://conductscience.org/library/papers/35779182PubMed
32152715Leishmaniasis immunopathology-impact on design and use of vaccines, diagnostics and drugs.Semin Immunopathol2020https://conductscience.org/library/papers/32152715PubMed
25268355Dual immune modulatory effect of vitamin A in human visceral leishmaniasis.PLoS One2014https://conductscience.org/library/papers/25268355PubMed
18587669Imunomodulative effect of liposomized muramyltripeptide phosphatidylethanolamine (L-MTP-PE) on mice with alveolar echinococcosis and treated with albendazole.Parasitol Res2008https://conductscience.org/library/papers/18587669PubMed
17015627Glibenclamide, a blocker of K+(ATP) channels, shows antileishmanial activity in experimental murine cutaneous leishmaniasis.Antimicrob Agents Chemother2006https://conductscience.org/library/papers/17015627PubMed
10817698Activity of the novel immunomodulatory compound tucaresol against experimental visceral leishmaniasis.Antimicrob Agents Chemother2000https://conductscience.org/library/papers/10817698PubMed
7628580Leishmania donovani in hamsters: stimulation of non-specific resistance by novel lipopeptides and their effect in antileishmanial therapy.Experientia1995https://conductscience.org/library/papers/7628580PubMed
3042625Liposomes as drug delivery system in the treatment of infectious diseases. Potential applications and clinical experience.Infection1988https://conductscience.org/library/papers/3042625PubMed
2387638Cyclosporin A treatment converts Leishmania donovani-infected C57BL/10 (curing) mice to a noncuring phenotype.Infect Immun1990https://conductscience.org/library/papers/2387638PubMed
2360812Suppression of both antimony-susceptible and antimony-resistant Leishmania donovani by a bis(benzyl)polyamine analog.Antimicrob Agents Chemother1990https://conductscience.org/library/papers/2360812PubMed
2044704Leishmania donovani in hamsters: stimulation of non-specific resistance by some novel glycopeptides and impact on therapeutic efficacy.Experientia1991https://conductscience.org/library/papers/2044704PubMed

Download CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/3988341

GET https://conductscience.org/api/papers/v1/3988341/references?page=2